D-0188-2025 Class II Ongoing
FDA drug recall D-0188-2025 was initiated by Rising Pharma Holding, Inc. on Dec 30, 2024 and is designated Class II. Reason for recall: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 42,527 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 15, 2025
- Initiation Date
- Dec 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 42,527 bottles
Product description
Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ
Reason for recall
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Distribution pattern
Nationwide
Code information
a) Lot# DT3023051A, exp. date Apr-25; b) DT3023025A, exp. date Jan-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0188-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026